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Abstract Cardiac myocytes undergo apoptosis under condition
of ischemia. Little is known, however, about the molecular path-
ways that mediate this response. We show that serum depriva-
tion and hypoxia, components of ischemia in vivo, resulted in
apoptosis of rat ventricular myoblast cells H9c2. Hypoxia alone
did not induce signi¢cant apoptosis for at least 48 h, but largely
increased the proapoptotic action of serum deprivation. H9c2
cells apoptosis is evidenced by an increase in terminal (TdT)-
mediated dUTP nick end-labeling-positive nuclei and by activa-
tion of caspases 3, 6, 7 and 9, and loss of mitochondrial func-
tions. In this model of simulated ischemia, represented by serum
deprivation plus hypoxia, cardiomyoblasts apoptosis was asso-
ciated with a p53-independent Bax accumulation and with a
down-regulation of Bcl-xL, whereas the levels of cIAP-1,
cIAP-2 and X-IAP proteins did not change. Phorbol-12-myris-
tate-13-acetate signi¢cantly reduced the induction of apoptosis,
inhibiting caspase 3 cleavage, Bax accumulation, Bcl-xL down-
regulation as well as restoring cell viability.
2 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Programmed cell death, or apoptosis, is a major form of
cell death that is used to remove excess, damaged or infected
cells throughout life. It is either an essential component of
normal development or a response to pathological disease
states. Apoptotic signaling varies from cell to cell, and di¡er-
ent apoptosis inducers may trigger distinct signaling pathways
[1]. A common and critical event in the execution phase of
apoptosis is the activation of a family of aspartate-speci¢c
proteases termed caspases [2,3], which participate in a cascade
where initiator caspases activate e¡ector caspases and ulti-
mately cleave a set of proteins, causing disassembly of the
cell. Caspases are synthesized as proenzymes that are acti-
vated by proteolytic processing [4]. Activation of caspases
may be regulated directly or indirectly by members of Bcl-2
family proteins [5,6]. Caspase activity can be induced by the
proapoptotic Bax and inhibited by the anti-apoptotic Bcl-2 or
Bcl-xL.
Apoptosis in the heart is a necessary mechanism for normal
remodelling and morphogenesis and is important in the devel-
opment of cardiac failure during injury due to ischemia/reper-
fusion and myocardial infarction [7]. Recent studies have in-
dicated that apoptotic death occurs in cardiac cells exposed to
a variety of damaging stimuli both in vitro and in the intact
heart in vivo [8^11]. Thus myocyte apoptosis is induced in
response to ischemia, as well as during tissue reperfusion in
rodents, rabbits and humans [9,12,13]. Despite the convincing
evidence that apoptosis occurs, the mechanism and signaling
pathway(s) activated by hypoxic/ischemic stimuli resulting in
cardiac cell apoptosis are poorly understood. Caspases and
Bcl-2 family proteins are involved in apoptotic cell death in
cardiomyocytes [14^16], but nothing is known about mole-
cules able to block the death of ischemic cardiomyocytes.
In the present study we report that H9c2 rat ventricular
myoblasts undergo apoptosis in conditions of simulated ische-
mia, represented by serum withdrawal plus hypoxia, that is
prevented by phorbol-12-myristate-13-acetate (PMA). The
protective e¡ect of PMA correlates with a marked down-reg-
ulation of the proapoptotic protein Bax and with an up-reg-
ulation of the anti-apoptotic protein Bcl-xL.
2. Materials and methods
2.1. Materials
Chemicals and biochemicals, Ac-DEVD-AMC (Ac-Asp-Glu-Val-
Asp-7-amino-4-methylcoumarin), DAPI (4,6-diamidino-2-phenylin-
dole) and Hoechst 33342 were from Sigma. Anti-caspase 6 and 7,
X-IAP, cIAP-1, cIAP-2 antibodies were purchased from New England
Biolabs; anti-caspase 3, Bax and p53 antibodies were obtained from
Santa Cruz; anti-Bcl-xL antibody from Trevigen. PMA, Go«6850
and Ac-IETD-AMC (Ac-Ile-Glu-Thr-Asp-7-amino-4-methylcouma-
rin) were from Alexis Biochemicals and JC-1 (5,5P,6,6P-tetrachloro-
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1,1P,3,3P-tetraethylbenzimidazol-carbocyanine iodide) from Molecular
Probes. z-DEVD-cmk (benzyloxycarbonyl-Asp-Glu-Val-Asp-chloro-
methylketone) and Ac-LEHD-AFC (Ac-Leu-Glu-His-Asp-7-amino-
4-tri£uoromethylcoumarin) were purchased from Calbiochem.
2.2. Cell culture and simulated ischemia
The H9c2 embryonal rat heart-derived cells [17] (obtained from
European Collection of Cell Cultures) were cultured in Dulbecco’s
modi¢ed Eagle’s medium (DMEM, Celbio) supplemented with 10%
heat-inactivated fetal calf serum (FCS). Subcon£uent cells (70^80%)
were subcultured 1:4. The cells were trypsinized, plated (10 000^12 000
cells/cm2) in 60-mm dishes for caspase activity assay or in 100-mm
dishes for immunoblotting and grown for 24 h before apoptotic treat-
ments. Simulated ischemia was achieved by culturing the cells in se-
rum-de¢cient DMEM in an anaerobic workstation (BugBox, Jouan,
France) saturated with 5% CO2/95% N2 at 37‡C for the indicated time
periods. The number of dead cells was determined by trypan blue
exclusion by counting cells with a Burker hemocytometer and was
calculated as the ratio of stained dead cells to the total amount of
cells.
2.3. Determination of caspase activity
The activity of caspase enzymes was measured by the cleavage of
the £uorogenic peptide substrates Ac-DEVD-AMC for caspase 3
(6, 7), Ac-IETD-AMC for caspase 8 and Ac-LEHD-AFC for caspase
9, during a 15-min incubation at 37‡C, as detailed elsewhere [18].
Caspase activity is expressed as U/mg protein, where 1 U is de¢ned
as the amount of enzyme activity cleaving 1.0 nmol of substrate per
min in the standard conditions described. Caspase activity is indicated
as DEVDase activity, since it includes the activity of all caspase en-
zymes that cleave the substrate Ac-DEVD-AMC (mainly e¡ector cas-
pases 3, 6, 7).
2.4. Mitochondrial reductase activity
Cellular reductase activity of live cultured cardiomyoblasts was de-
termined by measuring the reduction of MTT (3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromid) [19] by mitochondrial reduc-
tases, using the MTT assay kit from Boehringer Mannheim.
2.5. Measurement of mitochondrial membrane potential (v8m)
v8m was assessed using a £uorescent dye, the lipophilic cationic
probe JC-1 [20]. H9c2 cells were seeded (10 000 cells/well) in 96-well
plates and exposed to the treatments. At the end of incubation, car-
diac myocytes were incubated in DMEM containing 3 WM JC-1 for 30
min at room temperature in the dark. After staining, medium was
removed, cells were washed twice with PBS, resuspended in a total
volume of 200 Wl PBS and analyzed in a multilabel counter (Victor2,
Perkin Elmer). Collapse of v8m was examined for each sample using
535 nm (FL1) versus 590 nm (FL2) £uorescence. JC-1 forms aggre-
gates in cells, which leads to high values in FL2 £uorescence, indicat-
ing a normal mitochondrial potential. Loss of v8m leads to reduction
in FL2 £uorescence (aggregate state of JC-1) and a concomitant in-
crease in FL1 £uorescence (monomeric state of JC-1). Data were ex-
pressed as ratio of FL1/FL2 £uorescence. As positive control for loss
of v8m, cells were treated with 10 WM valinomycin for 20 min at
37‡C.
2.6. Western blotting
The cellular proteins were extracted in lysis bu¡er (20 mM HEPES,
pH 7.0, 5 mM dithiothreitol (DTT), 2 mM EDTA, 0.1% 3-[(3-chol-
aminodopropyl)dimethylammonio]-1-propanesulfonate, 0.1% Triton
X-100, 1 mM phenylmethylsulfonyl £uoride, 1 Wg/ml each aprotinin,
pepstatin and leupeptin), diluted 1:1 with Laemmli bu¡er, then dena-
turated by boiling. Aliquots corresponding to 25 Wg (Bax), 50 Wg
(caspase 3) or 80 Wg (caspases 6 and 7, p53, X-IAP, cIAP-1, cIAP-
2, Bcl-xL) protein were analyzed by SDS^PAGE (10% or 15% gel).
After blotting, the nitrocellulose membrane was blocked with 5% non-
fat dry milk for 1 h, washed with Tris-bu¡ered saline and probed
overnight at 4‡C (caspases 6 and 7, X-IAP, cIAP-1, cIAP-2, Bcl-xL)
or at room temperature for 60 min (caspase 3, Bax, p53) with the
speci¢c primary antibody. After further washing, the membrane was
incubated for 30 min with the secondary antibody (horseradish per-
oxidase-conjugated). After washing, immunoreactive bands were visu-
alized with an enhanced chemiluminescence kit (Amersham). Quanti-
tative analysis of immunoblotted bands was performed by means
densitometry (QuantiScan, Biosoft).
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Fig. 1. Deprivation of serum and oxygen induces apoptosis in H9c2
cells. A: H9c2 cells were incubated in standard DMEM (Ctrl) or in
serum-deprived DMEM (-FCS), either in normoxic or in hypoxic
conditions for the indicated times. Cells were then harvested and as-
sayed for caspase activity. B: H9c2 cells were incubated in standard
DMEM (Ctrl) or in serum-deprived DMEM (-FCS), either in nor-
moxic or in hypoxic conditions for 72 h. At the end of the incuba-
tion, cell death was assessed by trypan blue exclusion. C: H9c2 cells
were incubated in standard DMEM (Ctrl) or in serum-deprived
DMEM (-FCS), either in normoxic or in hypoxic conditions for the
indicated times. At the end of each time point, quantitative assay of
apoptotic cardiomyoblasts (TUNEL assay) was performed, as de-
scribed in Section 2. In all panels, the results represent meansS
S.E.M. of three determinations.
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2.7. DNA breaks detection by in situ end-labeling and nuclear staining
To label apoptotic nuclei, the 3P-OH end of DNA fragments were
visualized by the method of terminal transferase-mediated dUTP nick
end-labeling (TUNEL), using the Apoptosis Detection System £uo-
rescence kit (Promega, WI, USA) according to the manufacturer’s
instructions. The nuclei of apoptotic and non-apoptotic cells were
counterstained with DAPI (0.1 Wg/ml). The labeled cells were analyzed
by £uorescence microscopy. The percentage of apoptotic cells was
calculated as the ratio of the number of TUNEL-positive cells to
the total number of DAPI-stained cells, counted in three di¡erent
random ¢elds. To con¢rm myoblast apoptosis, nuclei were stained
with the karyophilic dye Hoechst 33342 (1 Wg/ml). The morphological
features of apoptosis (chromatin condensation and nuclear fragmen-
tation) were monitored by £uorescence microscopy.
3. Results
3.1. Deprivation of serum and oxygen triggers caspase activity
and apoptosis in H9c2 cells
During ischemia, multiple changes contribute to cellular
death. Among these are deprivation of nutrients, growth
and survival factors and oxygen. To study the e¡ects of these
stimuli, the cell line H9c2, which is derived from the embry-
onic rat heart, was exposed to culture conditions that mim-
icked ischemia. We tested the ability of serum and oxygen
deprivation to induce caspase activation, an early marker of
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Fig. 2. Caspase activity and mitochondrial dysfunction in H9c2 cells exposed to simulated ischemia. A: H9c2 cells were incubated in standard
DMEM (Ctrl) or in ischemic culture conditions (-FCS/hypoxia) for 24 h. Cells were then harvested and assayed for the activity of the caspases
3, 8 and 9 as described in Section 2. Results are expressed as percentage of the caspase activity measured in control cells, taken as 100%. The
panel reports the result obtained in one experiment, representative of three. B: H9c2 cells were incubated in standard DMEM (Ctrl) or in is-
chemic culture conditions (-FCS/hypoxia) and harvested after 24 h. Cell extracts were analyzed for caspase 3, 6 and 7 processing by Western
blotting. Results are representative of three independent experiments. C: H9c2 cells were incubated in standard DMEM (Ctrl) or in ischemic
culture conditions (-FCS/hypoxia) for 8, 24, 48 and 72 h. At the end of incubation, mitochondrial viability was assessed by the MTT reduction
assay. Results represent meansSS.E.M. (N=4), expressed as percentage of control, taken as 100%. D: H9c2 cells were incubated for 8 and
24 h in standard DMEM (Ctrl) or in ischemic culture conditions (-FCS/hypoxia). At the end of incubation, v8m was assessed as described in
Section 2. As a positive control of v8m collapse, H9c2 cells were treated with 10 WM of valinomycin (not shown). Data are meansSS.E.M.
(N=6) of results obtained in one experiment, and representative of three.
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apoptosis. Serum withdrawal induced a time-dependent in-
crease in caspase activity, that was ¢rst evident after 8 h of
incubation. Oxygen deprivation of cells cultured in serum-free
medium increased caspase activity signi¢cantly. Hypoxia
alone did not induce caspase activity with respect to the con-
trol cells during the time examined, in agreement with pre-
vious reports [21,22] (Fig. 1A). The caspase activation induced
by serum deprivation and hypoxia was accompanied by a
reduction in cell viability (Fig. 1B). Low oxygen concentra-
tions alone did not reduce cell viability of H9c2 cells, consis-
tent with the low caspase activity measured in hypoxic con-
ditions in the presence of serum. To rule out the possibility
that the loss of viability observed in hypoxic serum-starved
H9c2 cells was due to necrotic process, a TUNEL quanti¢ca-
tion of apoptotic cells was performed. Fig. 1C shows that
after 8 h of incubation no DNA strand break fragmentation
occurred in treated cells, whereas at the same time caspase
activity was already detectable. The percentage of apoptotic
cells increased in time-dependent manner in serum-starved
and in hypoxic serum-starved cells, with a precise correspon-
dence with the caspase activation and the loss of cellular via-
bility.
These data suggest that serum deprivation and hypoxia,
components of ischemia in vivo, induced apoptosis in H9c2
cells. In the light of these results on apoptosis induction, we
adopted in the following experiments a model of simulated
ischemia consisting of H9c2 cells cultured in hypoxic serum-
starved conditions.
3.2. Caspase activation in H9c2 cells cultured in hypoxic
serum-starved conditions is accompanied by
mitochondrial dysfunction
Activation of downstream caspase cascade may take place
either within death receptor complexes of the cytoplasmic
membrane involving the activation of the initiator caspase 8
or by a mitochondrion-dependent mechanism in the cytosol
involving the activation of the initiator caspase 9 [4]. There-
fore, we measured the activity of caspase 8 and caspase 9 by
the cleavage of the speci¢c £uorogenic peptide substrates in
H9c2 cells grown in hypoxic serum-deprived medium for 24 h.
Fig. 2A shows that caspase 9 activity is largely increased in
ischemic cells, whereas the degree of activation of caspase 8 is
much lower. Caspase 8 activity was not a¡ected at all after 8 h
of incubation (not shown).
Since the peptide sequence DEVD, used as a substrate in
the caspase 3 activity assay, is cleaved by caspase 3 and also
by caspases 6 and 7, e¡ector members of the caspase family,
we next examined if these caspases were activated. Under
control conditions, only the uncleaved proforms of endoge-
nous caspases were detected by immunoblotting (Fig. 2B).
Exposure of H9c2 cells to serum withdrawal and to hypoxia
induced proteolytic cleavage of caspases, as revealed by the
appearance of the characteristic fragment at p20 kDa of cas-
pase 3 and by the disappearance of the uncleaved precursors
of caspases 6 and 7. This proteolytic activation was nearly
complete after 24-hours incubation.
The apoptotic responses involve mitochondrial dysfunction,
so we evaluated an impairment in mitochondrial functions by
the MTT assay. The conversion of the tetrazolium dye MTT
to its reduced form, a reaction mediated by mitochondrial
reductases, was used as an index of mitochondrial viability.
The simulated ischemia induced a time-dependent decrease of
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Fig. 3. PMA inhibits apoptosis in H9c2 cells exposed to simulated
ischemia. A: H9c2 cells were incubated for 24 h in standard
DMEM (Ctrl) or in ischemic culture conditions (-FCS/hypoxia), in
absence or in presence of 160 nM PMA or 100 WM z-DEVD-cmk.
At the end of the incubation, cells were harvested and assayed for
caspase activity. Results represent meansSS.E.M. (N=3). B: H9c2
cells were incubated for 24 h in standard DMEM (Ctrl) or in ische-
mic culture conditions (-FCS/hypoxia), in absence or in presence of
160 nM PMA. Cell extracts were analyzed for caspase 3 processing
by Western blotting. C: H9c2 cells were incubated in standard
DMEM (Ctrl) or in ischemic culture conditions (-FCS/hypoxia), in
absence or in presence of 160 nM PMA. At the indicated times, cell
death was assessed by trypan blue exclusion. Results represent
meansSS.E.M. (N=3).
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MTT reductase activity, that was ¢rst evident after 24 h of
initiation of the apoptotic stimulus (Fig. 2C). In the light of
these changes in mitochondrial function [5,6], we assessed
whether there was any decrease in v8m using the potential-
sensitive dye JC-1. We observed a loss of v8m after 24-h
incubation in ischemic conditions (Fig. 2D). Loss of mem-
brane potential was not detectable before 24 h. After 8 h of
incubation we were not able to measure any signi¢cant de-
crease in MTT reductase activity as well as in v8m suggesting
that mitochondrial dysfunction follows caspase activation
during apoptosis of H9c2 cells induced by serum deprivation
plus hypoxia.
3.3. PMA inhibits apoptosis induced by simulated ischemia in
H9c2 cells
The phorbol ester PMA is known to modulate apoptosis
induced by various stimuli [23^25]. In order to assess whether
PMA could prevent apoptosis induced by simulated ischemia,
we determined the e¡ect of PMA on caspase activation, that
represents an early event in this model of apoptosis. H9c2
cells were incubated for 24 h in hypoxic serum-deprived
DMEM in the presence of 160 nM PMA, given at the begin-
ning of the incubation. As shown in Fig. 3A, PMA signi¢-
cantly reduced the induction of caspase activity elicited by
simulated ischemia. The e¡ect of PMA was similar to that
of 100 WM z-DEVD-cmk, an inhibitor of e¡ector caspases.
Exposure of control cells to PMA and z-DEVD-cmk did
not modify basal caspase activity. PMA also inhibited the
processing of procaspase 3 (Fig. 3B) and partially restored
cell viability (Fig. 3C) in ischemic H9c2 cells. PMA blocked
caspase activation also in serum-deprived cells, incubated in
normoxic culture conditions (not shown).
3.4. Bcl-2 family proteins in apoptosis induced by simulated
ischemia in H9c2 cells
Bcl-2 family proteins play a critical role in the decision of
the cell to die or survive by acting at multiple levels with a
prompt impact on caspase activation [5,6]. Therefore we in-
vestigated the e¡ect of serum withdrawal and hypoxia on the
expression of the proapoptotic protein Bax in H9c2 cells. Six
hours of serum deprivation induced an accumulation of the
Bax protein that was further increased by hypoxia to about
1.4 times the control level, as determined by densitometric
scanning of immunoblots. Bax levels continued to increase
until 24 h of incubation (not shown). Fig. 4A depicts the
separated e¡ect of serum deprivation and hypoxia, compo-
nents of simulated ischemia model that we used, on the Bax
level after 24 h of incubation. In cells incubated at low oxygen
concentration alone for the same time period, the level of Bax
protein was similar to the control cells, whereas it was in-
creased about 2.6 times in ischemic cells. Since hypoxia in
some experimental models may increase levels of the proapop-
totic protein p53 [21,26], and p53 itself can induce Bax [27],
we next examined whether hypoxia and/or serum deprivation
could in£uence p53 expression. Fig. 4A shows that hypoxia
itself failed to cause p53 accumulation, while serum with-
drawal, independently by hypoxia, induced a down-regulation
of p53. This down-regulation is almost complete after 15 min
of incubation (data not shown). These data suggest that in the
present model of simulated ischemia, the induction of H9c2
cells apoptosis is associated to a signaling pathway involving
Bax and independent of p53.
We next examined the e¡ect of PMA on the Bcl-2 family
proteins. Fig. 4B shows that PMA treatment of ischemic H9c2
cells for 24 h blocked Bax accumulation, whose level was
lower than in control cells. An opposite trend was found
when the expression of anti-apoptotic protein Bcl-xL was
examined: after 24 h of simulated ischemia we detected a
strong down-regulation of Bcl-xL that was inhibited by
PMA treatment. Exposure of control cells to PMA alone
did not change basal levels of Bax and Bcl-xL proteins. We
could not notice signi¢cant change in the protein levels of the
proapoptotic protein Bid (time points from 6 to 24 h were
examinated), according to the weak activation of caspase 8
(Fig. 4B).
Inhibitor of apoptosis protein (IAP)-related proteins have
been demonstrated to modulate activation of apoptosis by
directly inhibiting activated e¡ector caspases, such as caspases
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Fig. 4. E¡ect of simulated ischemia and PMA on the level of some Bcl-2 family proteins. A: H9c2 cells were incubated in standard DMEM
(Ctrl) or in serum-deprived DMEM (-FCS), either in normoxic or in hypoxic conditions for 24 h. At the end of the incubation, cell extracts
were prepared and analyzed by Western blotting for Bax and for p53 proteins. B: H9c2 cells were incubated for 24 h in standard DMEM
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were prepared and analyzed by Western blotting for Bid, Bax and Bcl-xL proteins. Results are representative of three independent experiments.
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3, 6 and 7 [28]. Recently, PMA has been reported to inhibit
apoptosis by sustaining expression levels of the IAP-proteins
[29]. However, in our experimental model expression levels of
cIAP-1, cIAP-2 and X-IAP proteins was not altered by ische-
mic conditions (not shown).
4. Discussion
Many recent studies have indicated that either ischemia
alone or in combination with reoxygenation can trigger car-
diomyocyte apoptosis in a way similar to the other cellular
stresses, such as growth factor withdrawal, UV radiation and
chemotherapeutic agents [21,22,30,31]. The mechanisms by
which the ischemic insult induces apoptosis are not well
understood. Moreover, little is known about pharmacological
agents that target the ischemia-induced apoptotic pathways in
the heart and can exert a cardioprotective e¡ect. In the
present study we show that ischemia induces apoptosis in
H9c2 myogenic cells that is accompanied by Bax up-regula-
tion and Bc-xL down-regulation, mitochondrial dysfunction
and activation of all e¡ector caspases 3, 6 and 7.
The ischemic model of cultured cardiomyoblasts used in
this study combines the following two properties of ischemia:
survival-growth factor withdrawal and hypoxia. Between
these stimuli, serum deprivation is the stronger one in H9c2
cells, indicating that, as in other cell types, cardiac myocytes
undergo apoptosis in the absence of de¢ned growth factors. In
this regard, recently various trophic factors have captured the
attention of researchers due to their possible role in cardio-
myocyte survival. Factor such as interleukin-6, cardiotrophin
1 and insulin-like growth factor 1 have been shown to be
cardioprotective and to inhibit cardiac myocyte apoptosis
[32^34].
In H9c2 cells hypoxia alone is a very weak apoptotic stim-
ulus. However, hypoxia largely increases the proapoptotic ac-
tion of serum withdrawal, and can be seen as a modulator of
the apoptotic process. Previous reports have documented the
need for long term hypoxia (24^72 h) for the appearance of
signi¢cant apoptosis in neonatal rat cardiac myocytes [22].
This prolonged viability in the face of severe hypoxia suggests
the presence of intrinsic mechanisms that protect cardiac my-
ocytes from hypoxia-induced apoptosis. Some of this relative
resistance to hypoxia may result from the high levels of en-
dogenous apoptosis inhibitors in neonatal and embryonal car-
diac cells, such as the cellular FLICE-inhibitory proteins and
ARC (apoptosis repressor with caspase recruitment domain).
In this regard, ARC expression in H9c2 cells was shown to
decrease in association with activation of ischemia-induced
apoptosis [35].
In the model of simulated ischemia-induced apoptosis de-
scribed in this paper, a de¢nite sequence of events take place.
At earlier time points (6^8 h) Bax begins to accumulate and
caspases are activated. After 24 h mitochondria damage is
well evident and cells can be detected with signs of nuclear
apoptosis. At later time points (48^72 h) an increasing num-
ber of cells die.
It appears unlikely that the death receptor pathway is in-
volved in ischemia-induced apoptosis of H9c2 cells since we
could not detect cellular events characteristic of this pathway.
Actually, caspase 8 activation is very weak and the Bid proa-
poptotic protein is not processed [30]. The activation of e¡ec-
tor caspases 3, 6, 7 in this model it is likely to occur via the
mitochondrial death pathway, as suggested by activation of
caspase 9 and Bax accumulation.
Bcl-2 family proteins play important roles in the regulation
of apoptosis and are important modulators of cardiac myo-
cyte apoptosis [16,36]. The main site of action of Bcl-2 family
proteins appears to be the mitochondrion. Homodimers of
Bcl-2 or Bcl-xL associate with the mitochondrial membrane
and in£uence membrane permeability [37]. The protective ef-
fect of Bcl-2 or Bcl-xL on mitochondria permeability is lost
when Bcl-2 or Bcl-xL homodimers are sequestered by the
formation of Bcl-2/Bax heterodimers [34]. In H9c2 cells the
level of Bcl-2 protein is extremely low [37], so we examined
the expression of another anti-apoptotic protein, i.e. Bcl-xL
and we show here for the ¢rst time that Bcl-xL is expressed in
H9c2 cells. The induction of apoptosis by simulated ischemia
is associated with Bcl-xL down-regulation, and with an in-
creased abundance of Bax. It is possible that induction of
apoptosis involves a concerted action of Bax and Bcl-xL on
caspase activation. However, it should be stressed that at the
present, only speculations on the role of these proteins in ap-
optosis of ischemic H9c2 cells can be drawn. In this experi-
mental model, apoptosis and Bax accumulation were com-
pletely independent of p53 protein [27]. Actually, there was
no change in p53 protein during exposure of myoblasts to
hypoxia alone; moreover, serum starvation itself induced a
very rapid down-regulation of p53, before any change in
Bax protein level. The role of p53 in apoptosis is highly de-
pendent on cell type and cell context [21,26], and several path-
ways of apoptosis are independent of p53, even in cardiac
myocytes [38].
Since apoptosis represents an active, gene-directed mecha-
nism, it should be possible to control this process for thera-
peutic purposes. In this regard, we tested the hypothetical
protective e¡ect of PMA. PMA, a phorbol ester and activator
of classical and novel protein kinase C (PKC) isoforms [39],
has been reported to induce proliferation or di¡erentiation in
di¡erent cell lines [40] and to be associated with cardiac hy-
pertrophy [41]. In addition PMA is able to modulate apopto-
sis in di¡erent models [23^25]. In several cases, evidence has
been provided that the anti-apoptotic e¡ect of PMA is medi-
ated through PKC [42]. We show here that PMA attenuates
ischemia-induced apoptosis in H9c2 cells, inhibiting caspase 3
activation and reducing cytotoxicity. This result suggests that
the cell survival signal imparted by PMA could interfere with
the apoptotic signal pathway activated by ischemia in myo-
blastic cells. PMA also abrogated the Bax accumulation and
the down-regulation of Bcl-xL that follows exposure to ische-
mia. This e¡ect on Bcl-2 family proteins level may be an
important component of the anti-apoptotic action of PMA.
Previous reports have suggested that PMA may exert its anti-
apoptotic e¡ect by inducing phosphorylation and inactivation
of the proapoptotic Bcl-2 family member Bad [43]. It has also
been reported that PMA induces Bcl-2 phosphorylation [44]
and that PMA elicits a rapid decline of the steady state level
of Bax in murine macrophages [25]. Moreover the anti-apo-
ptotic e¡ect of PMA observed in our experimental model may
involve an active PKC protein. In fact, the treatment of is-
chemic cells with a generic PKC inhibitor Go«6850 [45],
blocked the inhibitory e¡ect of PMA on caspase activity (un-
published data). Studies are being in progress to explore the
role of PKC proteins in this experimental model. Elucidation
of the details by which PMA can inhibit apoptosis in cardiac
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myocytes may suggest novel strategies for the treatment of
ischemic heart disease.
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